Capricor Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne

 -Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-

-FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting-

-Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA-

-Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at 8:30 a.m. ET-

Virtual Investor Webcast and Conference Call

Capricor management will host a virtual investor webcast and conference call with slides on Monday, April 29, 2024, at 8:30 a.m. ET. To participate in the conference call, please dial 888-886-7786 (domestic/toll-free) or 416-764-8658 (international) and reference the conference ID: 34112256. Participants can use guest dial-in numbers above to be answered by an operator or click the Call me™ link for instant telephone access. To participate via webcast, please click here to view the slides. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

https://www.globenewswire.com/news-release/2024/04/24/2868646/0/en/Capricor-Therapeutics-Announces-Positive-Type-B-Meeting-with-FDA-for-CAP-1002-Program-for-Duchenne-Muscular-Dystrophy.html